| First Author | Kim HW | Year | 2022 |
| Journal | Theranostics | Volume | 12 |
| Issue | 7 | Pages | 3316-3328 |
| PubMed ID | 35547746 | Mgi Jnum | J:338842 |
| Mgi Id | MGI:7278272 | Doi | 10.7150/thno.69684 |
| Citation | Kim HW, et al. (2022) NAD(+)-boosting molecules suppress mast cell degranulation and anaphylactic responses in mice. Theranostics 12(7):3316-3328 |
| abstractText | Nicotinamide adenine dinucleotide (NAD(+)) acts as a cofactor for multiple biological processes. While previous research has revealed that the NAD(+) declines associated with aging contributes to an impairment of immune cells, its role in mast cell function, especially in response to an anaphylactic condition, has remained unexplored. We tested whether the restoration of cellular NAD(+) concentration by the supplementation of NAD(+) boosting molecules prevented mast cell degranulation and anaphylactic responses. Methods: Bone marrow derived mast cells (BMMCs) and human cord blood derived mast cells were treated with NAD(+) precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), and FcepsilonRI downstream signaling was assessed. Animal models of passive systemic anaphylaxis (PSA) and passive cutaneous anaphylaxis (PCA) were used to investigate the effects of NAD(+) precursors in the anaphylactic responses of mice. Results: Treatment of murine BMMCs and human cord blood derived mast cells with NAD(+) precursors repressed intracellular signaling downstream of FcepsilonRI, as well as the release of inflammatory cytokines and lipid mediators. The intraperitoneal administration of NMN or NR also markedly attenuated IgE-mediated anaphylactic responses in mouse models of PSA and PCA. These beneficial effects of NAD(+) precursors, however, were attenuated in mast cell-specific Sirt6 knockout mice, indicating a Sirt6 dependency for their action. Conclusion: NAD(+) precursors may serve as an effective therapeutic strategy that limits mast cell-mediated anaphylactic responses. |
